Over the next 5 years, we anticipate that the population of patients undergoing bariatric surgery will grow immensely. Unfortunately, SSI pathogens are becoming more resistant to standard antimicrobials. In particular, the continuing spread of community-acquired MRSA and extended-spectrum β-lactamase-producing Gram-negative bacilli will make the delivery of effective antimicrobial prophylaxis more challenging, particularly in the obese population. Public reporting of infection rates and decreased insurance reimbursements for hospital-acquired infections, such as SSIs, might have a profound effect on the bariatric surgery population, as these patients are generally at 'high risk' for SSIs and have a relatively high frequency of comorbid conditions, increasing their risk for SSIs.
Financial & competing interests disclosure
Keith Kaye is a consultant and on the speakers bureau for Merck, and has received research support. Keith Kaye is also on the speakers bureau for Pfizer and has received research support from them, he has also received a grant from the NIH (K23-AG023621-05). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.
Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):317-328. © 2010 Expert Reviews Ltd.
Cite this: Preventing Surgical Site Infections after Bariatric Surgery: Value of Perioperative Antibiotic Regimens - Medscape - Jun 01, 2010.